Project
Abbvie M16-852 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and
Ongoing - recruitment closed ยท 2019 until 2024
Rubbert-Roth Andrea, Hutz Carina Liane, Bartz-Batliner Mira, Neumann Thomas, Peischl Riana, Sasselli Clelia
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Ongoing - recruitment closed
Start Date
2019
End Date
2024
Financing
Industry
Study Design
Study M16-852 is a Phase 3, global, multicenter, randomized, double-blind, PBO-controlled study.
Approximately 420 subjects will be enrolled into this study.
Keywords
active GCA, upadacitinib
Brief description/objective
Giant Cell Arteritis: Phase 3 Safety and Efficacy Study of Upadacitinib in
Subjects with Giant Cell Arteritis